YaoGeJu

YaoGeJuCDE public lists · weekly counts

National Drug-Review Weekly

The available CDE acceptance records list 419 drug applications between 11 November 2026 and 17 November 2026 (data as of 23 November 2026). Of these, generic applications numbered 73, covering 50 drug names.

2026/11/11 – 2026/11/17

Period
2026/11/11 to 2026/11/17, 7 days inclusive
Data as of
2026/11/23
Loaded records
95,213 acceptance records, 11,351 under review now
Source
Public data from the CDE acceptance list and under-review list
New acceptances this week
419
Drugs with new generic filings (by drug name, de-duplicated)
50
Accepted this week, now under review
419

DefinitionAcceptance numbers accepted this week that are still on CDE's under-review list at the data cut-off; counted by acceptance date.

Names with a public page are linked.

New acceptances this week

By application type and drug type

419filings, 73 of them generic

By application type

Application typeFilings
Supplement215
New drug89
Generic73
Import32
Unspecified5
Import re-registration5

By drug type

Drug typeFilings
Chemical drug243
TCM98
Therapeutic biologic67
Biologic6
Prophylactic biologic5

DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.

Most new generic filings, by drug

50 drugs with new generic filings; top 10 listed

#DrugNew generic filingsFiling companiesUnder review, all years
1Polyvinyl Alcohol Eye Drops3226
2Mirogabalin Besilate Tablets3264
3Fosfomycin Sodium For Injection3116
4西诺氨酯片 · No verified English name3123
5Tafluprost Eye Drops223
6Rosuvastatin Calcium and Ezetimibe Tablets (I)227
7Trazodone Hydrochloride Sustained-release Tablets2222
8Buprenorphine Hydrochloride and Naloxone Hydrochloride Sublingual Tablets212
9Ethyl Iosapentate Capsules2125
10Dotinurad Tablets2156

DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.

Most new acceptances, by company

250 companies with new acceptances; top 10 listed

#Company (first applicant)FilingsDrugsGeneric
1Henan Pu Rui Pharma Co., Ltd. romanized1480
2Jiangsu Hengrui Pharmaceuticals Co.,Ltd.730
3Eli Lilly and Company630
4CISEN PHARMACEUTICAL CO., LTD.633
5Novo Nordisk A/S610
6Suzhou Ya Sheng Pharma Co., Ltd. romanized610
7Shandong Bu Zhang Pharmaceutical Co., Ltd. romanized550
8Anhui Sheng Jing Cheng Hui Yao Pharma Co., Ltd. romanized530
9Boehringer Ingelheim International GmbH520
10Beijing Tong Ren Tang Co., Ltd. Tong Ren Tang Pharmaceutical Factory romanized420

DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.

Under-review list changes

Based on changes in CDE's under-review list

Entered review this week
419
Left the under-review list this week
565

Of these, NMPA published approval-document delivery for 232 (including 222 supplemental applications, not counted as new marketing approvals) and notification delivery for 16; the outcome of the other 317 is to be checked.

Most filings leaving review, by company

Most filings leaving review, by company
#Company (first applicant)FilingsDrugs
1Bai Ji Shen Zhou (Suzhou) Bio Technology Co., Ltd. romanized133
2Jiangsu Hengrui Pharmaceuticals Co.,Ltd.93
3AbbVie Inc.81
4Rui Li Shi Wan Ting Min Xin Pharmaceutical Co., Ltd. romanized71
5Luo Yang Yi Long Pharma Co., Ltd. romanized66
6Shijiazhuang No.4 Pharmaceutical Co., Ltd.65
7Novartis Pharma AG64
8Shanghai Han Sen Biopharmaceuticals Technology Co., Ltd. romanized55
9Li Shi Zhen Pharmaceuticals Group Co., Ltd. romanized54
10Shanghai Kai Mao Biopharmaceuticals Co., Ltd. romanized51

Most filings entering review, by company

Most filings entering review, by company
#Company (first applicant)FilingsDrugs
1Novo Nordisk A/S112
2Beijing Tong Ren Tang Co., Ltd. Tong Ren Tang Pharmaceutical Factory romanized84
3F. Hoffmann-La Roche Ltd82
4Jiangsu Hengrui Pharmaceuticals Co.,Ltd.73
5Henan Pu Rui Pharma Co., Ltd. romanized64
6CISEN PHARMACEUTICAL CO., LTD.63
7SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.61
8Suzhou Ya Sheng Pharma Co., Ltd. romanized61
9Shandong Bu Zhang Pharmaceutical Co., Ltd. romanized55
10Yichang Humanwell Pharmaceutical Co., Ltd.53

DefinitionEntered review = acceptance numbers first listed on CDE's under-review list this week, excluding numbers already listed on the record start date (2026/10/22). Left review = acceptance numbers last listed this week and no longer listed at the data cut-off; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.

Class 3 and new-drug acceptances

137 this week

AcceptedDrugApplicants
2026/11/17Import · Class 1 LUM-201胶囊 · No verified English nameJXHL2600517 Lumos Pharma LLC; ICON Clinical Research (Beijing No. 2) Co. Ltd.
2026/11/17Import · Class 1 LUM-201胶囊 · No verified English nameJXHL2600516 Lumos Pharma LLC; ICON Clinical Research (Beijing No. 2) Co. Ltd.
2026/11/17Import · Class 1 LUM-201胶囊 · No verified English nameJXHL2600515 Lumos Pharma LLC; ICON Clinical Research (Beijing No. 2) Co. Ltd.
2026/11/17Generic · Class 3 恩那度司他片 · No verified English nameCYHS2602837 Shandong Loncom Pharmaceutical Co., Ltd.
2026/11/17Generic · Class 3 恩那度司他片 · No verified English nameCYHS2602836 Shandong Loncom Pharmaceutical Co., Ltd.
2026/11/17Generic · Class 3 血管紧张素Ⅱ注射液 · No verified English nameCYHS2602828 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
2026/11/17New drug · Class 1 XKH001注射液 · No verified English nameCXSL2601280 Xin Kang He Biopharmaceuticals (Beijing) Co., Ltd. romanized; Beijing Xin Kang He Biopharmaceuticals Technology Co., Ltd. romanized
2026/11/17New drug · Class 1 DC01注射液 · No verified English nameCXSL2601279 Chengdu Bo An Zhi Yan Xi Bao Bio Technology Co., Ltd. romanized; Sichuan Zhong Ke Ding Yao Xi Bao Technology Co., Ltd. romanized
2026/11/17New drug · Class 1 PTT-936口服冻干粉 · No verified English nameCXHL2601446 Beijing Yan Ming Bio Technology Co., Ltd. romanized
2026/11/17New drug · Class 2.1; 2.2; 2.4 HW-N2001注射液 · No verified English nameCXHL2601445 HARWAY PHARMA CO.,LTD.
2026/11/17New drug · Class 1 ZL-69胶囊 · No verified English nameCXHL2601444 Chengdu Ze Ling Biopharmaceuticals Technology Co., Ltd. romanized
2026/11/17New drug · Class 1 ZL-69胶囊 · No verified English nameCXHL2601443 Chengdu Ze Ling Biopharmaceuticals Technology Co., Ltd. romanized
2026/11/17New drug · Class 1 ZL-69胶囊 · No verified English nameCXHL2601442 Chengdu Ze Ling Biopharmaceuticals Technology Co., Ltd. romanized
2026/11/16Import · Class 1 Zenagamtide片 · No verified English nameJXSL2600322 Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd
2026/11/16Import · Class 1 Zenagamtide片 · No verified English nameJXSL2600321 Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd
2026/11/16Import · Class 1 Zenagamtide片 · No verified English nameJXSL2600320 Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd
2026/11/16Import · Class 1 Zenagamtide片 · No verified English nameJXSL2600319 Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd
2026/11/16Import · Class 1 Zenagamtide片 · No verified English nameJXSL2600318 Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd
2026/11/16Import · Class 1 Zenagamtide片 · No verified English nameJXSL2600317 Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd
2026/11/16Import · Class 1 PF-08634404 · No verified English nameJXSL2600316 Pfizer Inc.; Pfizer (Beijing) Research and Development Co. Ltd.
2026/11/16Import · Class 1 BI 3034701注射液 · No verified English nameJXHL2600514 Boehringer Ingelheim International GmbH; Boehringer Ingelheim (China) Investment Co. Ltd
2026/11/16Import · Class 1 BI 3034701注射液 · No verified English nameJXHL2600513 Boehringer Ingelheim International GmbH; Boehringer Ingelheim (China) Investment Co. Ltd
2026/11/16Import · Class 1 BI 3034701注射液 · No verified English nameJXHL2600512 Boehringer Ingelheim International GmbH; Boehringer Ingelheim (China) Investment Co. Ltd
Import · Class 1 BI 3034701注射液 · No verified English name —
2026/11/16Generic · Class 3 Brexpiprazole Orally Disintegrating TabletsCYHS2602824 Yunpeng Pharmaceutical Group Co., Ltd.
2026/11/16Generic · Class 3 Brexpiprazole Orally Disintegrating TabletsCYHS2602823 Yunpeng Pharmaceutical Group Co., Ltd.
2026/11/16Generic · Class 3 亚硒酸钠注射液 · No verified English nameCYHS2602819 TC Pharmaceuticals (Jiangsu) Co., Ltd
2026/11/16Generic · Class 3 Benzbromarone TabletsCYHS2602817 Shouguang Fukang Pharmaceutical Co., Ltd.
2026/11/16Generic · Class 3 Dequalinium Chloride Buccal TabletsCYHS2602815 Huayi Pharmaceuticals (Anhui) Co., Ltd.
2026/11/16New drug · Class 1 韦立斯托赛注射液 · No verified English nameCXSS2600189 Shanghai Ai Sa Er Biopharmaceuticals Co., Ltd. romanized

107 more not listed (at most 30 rows).

For some entries, the drug or company page limits access to the acceptance date, filing number and applicants.

DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.

Subscribe to the weekly

No account needed.

The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.

A text version of this report, weekly, in the language you subscribe in. You will receive one confirmation email first; sending starts only after you click its link. Every issue carries an unsubscribe link.